Diabetes Discourse

Host: John J. Russell, MD

Guest: Anne Peters, MD, CDE

Many patients with type 2 diabetes mellitus cannot be controlled with standard insulin agents due to obesity, insulin resistance, high risk of hypoglycemia, low adherence due to high injection burden, and the need for frequent glucose monitoring. Drs. Peters and Russell will review patient cases, and share practical information on concentrated insulins, including criteria for selection, switching strategies and dosing regimens, providing true practice-based learning particularly for clinicians in different geographic locations with high incidence rates of diabetes.

Host: Matt T. Rosenberg, MD

Guest: Monica E. Peek, MD, MPH, MSC

Attaining and maintaining glycemic control continues to be very difficult for patients with type 2 diabetes. Please join Drs. Matt T. Rosenberg and Monica E. Peek as they discuss these issues.

Host: John J. Russell, MD

Guest: Wendy S. Lane, MD

In this interview, Dr. Lane will review the clinical evidence supporting combinations of GLP-1 receptor agonists with basal insulin for the treatment of type 2 diabetes.

Host: Jennifer Caudle, DO

Guest: Javier Morales, MD, FACP, FACE

In this case-based discussion, Dr. Morales will share insights from his clinical experience on selecting patients likely to benefit from treatment with fixed-ratio combinations of GLP-1 receptor agonists and basal insulin, as well as advice on how to start and titrate these agents.

Host: Matt Birnholz, MD

Guest: Javier Morales, MD, FACP, FACE

Guest: Wendy S. Lane, MD

Demonstration and Panel Discussion: We will present video demonstrations of how to administer fixed-ratio combinations of GLP-1 receptor agonists and basal insulin, accompanied by a panel discussion with Drs. Lane and Morales on strategies for overcoming barriers to injectable therapy for type 2 diabetes.

Host: Matt Birnholz, MD

Guest: Rishi P. Singh, MD

The past 40 years have witnessed great advancements in therapeutic options for treating diabetic retinopathy. Despite a number of effective treatment options, diabetic eye disease is one of the leading causes of vision loss in the United States, in part because many patients are not identified as needing therapy. In addition to counseling patients on the importance glucose control on maintaining vision, clinicians should emphasize the need for regular vision tests among patients with diabetes. Early detection offers the best long-term visual outcomes and is even more important with new treatments approved for the management of diabetic retinopathy. As a value added-resource, a specialized toolkit will also be included as a supplement to the webcast. The toolkit will provide for clinicians clinical practice guidelines and recommendations for screening and diagnosis. In addition, the toolkit will provide helpful information and resources for patients, their families and caregivers.

Guest: Janet B. McGill, MD, MA, FACE

The Centers for Disease Control and Prevention estimates that 9.3% of the US population has diabetes mellitus (DM), and that 27.8% of this population has undiagnosed DM. Patients with DM have twice the medical costs of those without DM, and the direct financial burden on the US healthcare system was $176 billion in 2012. All individuals with type 1 DM (5% of the diabetic population) require insulin to control blood glucose levels; in addition, many individuals with type 2 DM require insulin as the disease progresses. Exogenous insulin is available in rapid-, short-, intermediate-, and long-acting formulations, and the goals of therapy are to mimic endogenous insulin while reducing the risk for adverse events and complications. New routes of administration, such as oral and buccal, and new longer-acting insulins are in development to improve and optimize diabetes management. It is vital for clinicians who manage DM to have a thorough understanding of insulin therapy, including insulin physiology and its dysfunction seen in DM; an overview on current and emerging insulin therapies; and best practices on constructing insulin-based treatment regimens. This interactive activity will provide information on insulin physiology in individuals without DM, the physiologic dysfunction of insulin seen in patients ...

Host: John J. Russell, MD

Guest: Candis Morello, PharmD, CDE

Candis M Morello, Professor of Clinical Pharmacy at UC San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, joins Dr. John Russell to talk about team-based care integrations of certified diabetes educators to help empower diabetes patients and improve long-term outcomes.

Diabetes Discourse, a non-certified educational series, is brought to you by AstraZeneca, pushing the boundaries of science to create life-changing medicines for people with diabetes. Content of this diabetes education is produced and solely controlled by ReachMD. This series is intended for healthcare professionals only.

Brought to you by

Host: John J. Russell, MD

Guest: Serena Cardillo, MD

Host Dr. John Russell welcomes Dr. Serena Cardillo, Associate Professor of Medicine in the Division of Endocrinology, Diabetes, & Metabolism at Penn Medicine. Dr. Cardillo guides listeners through the challenges in treating diabetic patients whose blood glucose levels remain poorly controlled.

Diabetes Discourse, a non-certified educational series, is brought to you by AstraZeneca, pushing the boundaries of science to create life-changing medicines for people with diabetes. Content of this diabetes education is produced and solely controlled by ReachMD. This series is intended for healthcare professionals only.

Brought to you by

Host: John J. Russell, MD

Guest: Candis Morello, PharmD, CDE

Host Dr. John Russell welcomes Candis M. Morello, PharmD., CDE, FCSHP, Professor of Clinical Pharmacy and Associate Dean for Student Affairs at the Skaggs School of Pharmacy and Pharmaceutical Sciences. Dr. Morello explains the importance of patient education, communication, and motivation needed to instill a positive and healthy approach to diabetes care.

Diabetes Discourse, a non-certified educational series, is brought to you by AstraZeneca, pushing the boundaries of science to create life-changing medicines for people with diabetes. Content of this diabetes education is produced and solely controlled by ReachMD. This series is intended for healthcare professionals only.

Brought to you by